Skip to Content

BeiGene Ltd Ordinary Shares 06160

Morningstar Rating
HK$94.50 +2.25 (2.44%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

06160 is trading at a 567% premium.
Price
HK$92.66
Fair Value
HK$331.14
Uncertainty
High
1-Star Price
HK$813.95
5-Star Price
HK$17.39
Economic Moat
Kjgcpm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 06160 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
HK$92.25
Day Range
HK$92.5595.20
52-Week Range
HK$75.45139.90
Bid/Ask
HK$94.50 / HK$94.55
Market Cap
HK$129.99 Bil
Volume/Avg
832,278 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.79
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
10,000

Comparables

Valuation

Metric
06160
09939
06978
Price/Earnings (Normalized)
Price/Book Value
4.760.91
Price/Sales
5.79
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
06160
09939
06978
Quick Ratio
1.732.071.02
Current Ratio
2.082.101.05
Interest Coverage
−110.66−38.73
Quick Ratio
06160
09939
06978

Profitability

Metric
06160
09939
06978
Return on Assets (Normalized)
−7.03%−64.88%−24.88%
Return on Equity (Normalized)
−10.84%−97.47%−103.89%
Return on Invested Capital (Normalized)
−10.66%−75.42%−31.45%
Return on Assets
06160
09939
06978
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BzxczmlpByjq$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
XbhjqyhFqtmyc$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
WqhryrpgKtrlph$117.2 Bil
Moderna Inc
MRNA
MnmpwzwrkTpzm$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
BbqnxqypPbvlj$30.1 Bil
argenx SE ADR
ARGX
NpvbczgYqhq$28.0 Bil
BioNTech SE ADR
BNTX
VgdxgsfRjxs$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
MxbttzdKsbfz$16.0 Bil
United Therapeutics Corp
UTHR
BfrlyjmrHlwk$14.6 Bil
Incyte Corp
INCY
RmdhvpjbQpkymgh$13.0 Bil

Sponsor Center